Peregrine Capital Management LLC Has $6.96 Million Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Peregrine Capital Management LLC decreased its holdings in AtriCure, Inc. (NASDAQ:ATRCGet Rating) by 24.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 156,863 shares of the medical device company’s stock after selling 50,361 shares during the quarter. Peregrine Capital Management LLC owned 0.34% of AtriCure worth $6,962,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in ATRC. Invesco Ltd. raised its stake in shares of AtriCure by 17.5% in the 1st quarter. Invesco Ltd. now owns 2,865,409 shares of the medical device company’s stock valued at $188,171,000 after buying an additional 427,792 shares in the last quarter. First Light Asset Management LLC increased its position in shares of AtriCure by 35.8% during the 1st quarter. First Light Asset Management LLC now owns 1,364,812 shares of the medical device company’s stock worth $89,627,000 after purchasing an additional 359,823 shares in the last quarter. Macquarie Group Ltd. increased its position in shares of AtriCure by 17.3% during the 2nd quarter. Macquarie Group Ltd. now owns 1,356,531 shares of the medical device company’s stock worth $55,428,000 after purchasing an additional 199,788 shares in the last quarter. Granite Investment Partners LLC increased its position in shares of AtriCure by 83.7% during the 3rd quarter. Granite Investment Partners LLC now owns 407,191 shares of the medical device company’s stock worth $15,921,000 after purchasing an additional 185,481 shares in the last quarter. Finally, Bellevue Group AG increased its position in shares of AtriCure by 20.1% during the 1st quarter. Bellevue Group AG now owns 598,605 shares of the medical device company’s stock worth $39,310,000 after purchasing an additional 100,049 shares in the last quarter. Institutional investors and hedge funds own 95.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ATRC shares. Stifel Nicolaus dropped their target price on shares of AtriCure from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Wednesday, February 22nd. Needham & Company LLC reiterated a “buy” rating and set a $58.00 target price on shares of AtriCure in a research report on Wednesday, February 22nd. Canaccord Genuity Group dropped their target price on shares of AtriCure from $81.00 to $74.00 and set a “buy” rating for the company in a research report on Wednesday, February 22nd. StockNews.com began coverage on shares of AtriCure in a report on Thursday. They set a “hold” rating on the stock. Finally, BTIG Research decreased their price objective on shares of AtriCure from $65.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, February 22nd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $59.17.

AtriCure Trading Down 0.4 %

Shares of AtriCure stock opened at $39.20 on Friday. The firm has a 50-day moving average of $41.50 and a 200-day moving average of $42.03. The stock has a market cap of $1.83 billion, a PE ratio of -38.81 and a beta of 1.31. AtriCure, Inc. has a 52-week low of $32.51 and a 52-week high of $68.58. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.90 and a current ratio of 3.69.

AtriCure (NASDAQ:ATRCGet Rating) last announced its earnings results on Tuesday, February 21st. The medical device company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.09. The company had revenue of $88.00 million during the quarter, compared to analysts’ expectations of $87.90 million. AtriCure had a negative net margin of 14.06% and a negative return on equity of 10.18%. AtriCure’s quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.30) earnings per share. As a group, sell-side analysts forecast that AtriCure, Inc. will post -1.07 EPS for the current year.

AtriCure Company Profile

(Get Rating)

AtriCure, Inc engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration.

Recommended Stories

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.